Abstract:The CDKN2A/B genomic locus is associated with risk of human cancers and metabolic disease. Although the locus contains several important protein-coding genes, studies suggest disease roles for a lesser-known antisense lncRNA encoded at this locus, called ANRIL. ANRIL is a complex gene containing at least 21 exons in simians, with many reported linear and circular isoforms. Like other genes, abundance of ANRIL is regulated by epigenetics, classic transcription regulation, splicing, and post-transcriptional influences such as RNA stability and microRNAs. Known molecular functions of ANRIL include in cis and in trans gene regulation through chromatin modification complexes, and influence over microRNA signaling networks. Polymorphisms at the ANRIL gene are linked to risk for many different cancers, as well as risk of atherosclerotic cardiovascular disease, bone mass, obesity and type 2 diabetes. A broad array of variable reported impacts of polymorphisms on ANRIL abundance, splicing and function suggests that ANRIL has cell-type and context-dependent regulation and actions. In cancer cells, ANRIL gain of function increases proliferation, metastasis, cell survival and epithelial-mesenchymal transformation, whereas ANRIL loss of function decreases tumor size and growth, invasion and metastasis, and increases apoptosis and senescence. In metabolic disease, polymorphisms at the ANRIL gene are linked to risk of type 2 diabetes, coronary artery disease, coronary artery calcium score, myocardial infarction, and stroke. Intriguingly, with the exception of one polymorphism in exon 2 of ANRIL, the single nucleotide polymorphisms (SNPs) associated with atherosclerosis and diabetes are non-overlapping. Evidence suggests that ANRIL gain of function increases atherosclerosis; in diabetes, a risk-SNP reduced the pancreatic beta cell proliferation index. Studies are limited by the uncertain relevance of rodent models to ANRIL studies, since most ANRIL exons do not exist in mouse. Diverse cell-type-dependent results suggest it is necessary to perform studies in the relevant primary human tissue for each disease. Much remains to be learned about the biology of ANRIL in human health and disease; this research area may lead to insight into disease mechanisms and therapeutic approaches.

ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease

Association Between the LINC00673 Rs11655237 C> T Polymorphisms with Cancer Risk in the Chinese Population: A Meta-Analysis

Multiple Non-coding ANRIL Transcripts Are Associated with Risk of Coronary Artery Disease: a Promising Circulating Biomarker

ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers

Effect of Polymorphism on IL1A to Cancer Susceptibility: Evidence Based on 34,016 Subjects

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

Long Non-Coding RNA ANRIL Regulates Inflammatory Responses As a Novel Component of NF-κB Pathway.

ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders

Correction: Long Noncoding RNA ANRIL Regulates Endothelial Cell Activities Associated with Coronary Artery Disease by Up-Regulating CLIP1, EZR, and LYVE1 Genes.

Polymorphisms of a Novel Long Non-Coding RNA RP11-108K3.2 with Colorectal Cancer Susceptibility and Their Effects on Its Expression

[Research Advance of ANRIL on Atherosclerosis by Regulating Cell Proliferation and Apoptosis].

Long Noncoding RNA ANRIL As a Novel Biomarker of Lymph Node Metastasis and Prognosis in Human Cancer: a Meta-Analysis

Analysis of ANRIL Isoforms and Key Genes in Patients with Severe Coronary Artery Disease

Characterization of novel LncRNA P14AS as a protector of ANRIL through AUF1 binding in human cells

Variants in ANRIL gene correlated with its expression contribute to myocardial infarction risk.

Association of Long Non-Coding RNA Polymorphisms with Gastric Cancer and Atrophic Gastritis

ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer

Long Noncoding RNA ANRIL Could Be Transactivated by C-Myc and Promote Tumor Progression of Non-Small-cell Lung Cancer.

LncRNA-ANRIL Promotes Gastric Cancer Progression by Enhancing NF-kB Signaling.

Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.

The Lncrna ANRIL Regulates Endothelial Dysfunction by Targeting the Let‐7b/tgf‐βr1 Signalling Pathway